Highest-materiality recent filing
Stryker names COO Spencer Stiles CEO effective Jan. 1, 2027; Kevin Lobo moves to Executive Chair
Spencer Stiles, President and COO since January 2026, becomes CEO and a Board member on January 1, 2027; Kevin Lobo, CEO since October 2012, becomes Executive Chair.
Stryker Q2 2026: net sales $6.6B (+9.4%), adj EPS $3.69 (+17.9%), narrows FY guidance
Q2 net sales $6.6B, up 9.4% reported and 9.0% organic; MedSurg/Neuro +9.2% organic, Orthopaedics +8.6%.
Stryker Q1 net sales $6.0B up 2.6%; adjusted EPS down 8.5% to $2.60; maintains FY guidance
Net sales $6.0B (+2.6% reported, +2.4% organic); MedSurg/Neuro +5.0%, Orthopaedics +0.1%.
Incident identified March 11, 2026; caused business disruptions.
Stryker updates cyber incident: contained, no customer data accessed per Unit 42
Threat actor used malicious file to hide activity; file not capable of spreading internally or externally.
Stryker updates on cyber incident: operations disrupted, patient services unaffected
Cybersecurity incident affecting Microsoft environment disclosed March 11; CISO provided update March 12.
Stryker reports global cybersecurity incident affecting Microsoft systems; investigation ongoing
Incident detected March 11, 2026; global disruption to Microsoft environment; no ransomware or malware; contained.
Stryker reports Q4 2025 sales $7.2B, +11% organic; 2026 outlook 8-9.5% organic growth
Q4 reported EPS $2.20 (+56% YoY); adjusted EPS $4.47 (+11.5%).
Stryker Q3 net sales +10.3% to $6.1B; raises FY 2025 guidance
Reported EPS $2.22 (+2.8%); adjusted EPS $3.19 (+11.1%).
Stryker Q2 2025: net sales $6.0B +11.1%, adj EPS $3.13 +11.4%, raises FY guidance
Net sales $6.0B +11.1% reported (+10.2% organic); MedSurg/Neuro +17.3%, Orthopaedics +2.0% (ex-spinal +10.7%).
Reported net sales $5.9B (+11.9% YoY); organic net sales +10.1%.
Stryker completes $4.94B cash acquisition of Inari Medical
Closed acquisition of Inari Medical for ~$4.94 billion in cash on Feb 19, 2025.
Stryker issues $3B in notes; $1.8B earmarked for Inari Medical acquisition
Issued $500M 4.550% notes due 2027, $700M 4.700% notes due 2028, $800M 4.850% notes due 2030, $1B 5.200% notes due 2035.
Stryker Q4 adjusted EPS up 15.9% to $4.01, organic sales +10.2%; guides 2025 8-9% growth
Reported EPS fell 52.7% to $1.41 due to $818M goodwill/impairment charges on Spine; adjusted EPS rose 15.9% to $4.01.
Stryker to acquire Inari Medical for $80/share cash, ~$4.9B equity value
Stryker will pay $80 per share in cash for all outstanding Inari shares; total fully diluted equity value ~$4.9B.
Stryker Q3 beats: adj EPS $2.87 (+16.7%), sales $5.5B (+11.5% organic), raises FY guidance
Reported net sales $5.5B, +11.9% reported, +11.5% organic; adjusted EPS $2.87, +16.7%.
Stryker Q2 2024: organic sales +9.0%, adj. EPS $2.81, raises FY guidance
Net sales $5.4B (+8.5% reported, +9.0% organic); MedSurg Neuro +9.7% organic, Ortho Spine +8.0% organic.
Reported EPS $2.05 (+33.1%); adjusted EPS $2.50 (+16.8%).
Stryker Q4 organic sales up 11.4%; FY23 revenue $20.5B; guides FY24 adj EPS $11.70-$12.00
Q4 organic net sales growth 11.4% to $5.8B; full year organic growth 11.5% to $20.5B.
Stryker Q3 net sales $4.9B (+9.6%), adjusted EPS $2.46 (+16.0%), raises FY guidance
Reported net sales $4.9B, +9.6% YoY; organic net sales +9.2%.
Net sales $5.0B, +11.2% reported, +11.9% organic; adj. EPS $2.54 (+12.9%).
Stryker Q1 organic sales +13.6%; raises FY growth guidance to 8-9%
Reported net sales $4.8B, +11.8% reported, +13.6% organic; MedSurg/Neuro +12.4%, Ortho+Spine +15.2%.
Stryker Q4 organic sales +13.2%, adj. EPS $3.00; FY23 adj. EPS guide $9.85-10.15
Q4 reported sales $5.2B (+10.7% YoY); organic sales +13.2% driven by MedSurg and Neurotechnology (+16.9% organic).
Stryker Q3 organic sales +9.9% to $4.5B; adj EPS $2.12 -3.6%; guides FY adj EPS $9.15-$9.25
Net sales $4.5B (+7.7% reported, +9.9% organic); MedSurg & Neuro +10.8% organic, Ortho & Spine +8.7%.
Stryker Q2 organic sales +6.1% to $4.5B; lowers FY adjusted EPS guidance to $9.30-$9.50
Reported net sales of $4.5B (+4.6% YoY); organic net sales +6.1%.
Stryker Q1 sales up 9.2% organic to $4.3B; lowers adjusted EPS guidance to lower end of $9.60-$10.00
Reported net sales $4.3B (+8.1%), organic +9.2%; MedSurg +10.8%, Orthopaedics and Spine +7.2%.
Stryker completes acquisition of Vocera Communications for ~$3.1B
Completed acquisition of Vocera Communications on Feb 23, 2022 for total consideration of ~$3.1B including repayment of convertible notes.
Stryker Q4 sales $4.7B (+10.3%), FY21 adj. EPS $9.09 (+22.3%); forecasts FY22 adj. EPS $9.60-10.00
Q4 net sales $4.7B, +10.3% YoY; organic +9.0% vs 2020, +6.2% vs 2019.
Stryker agrees to acquire Vocera Communications for $79.25 per share in cash
Stryker to acquire Vocera Communications for $79.25 per share in cash via tender offer and merger.
Stryker Q3: adj EPS $2.20 (+2.8%); organic sales +4.5%; China impairment $105M; guidance revised
Net sales $4.2B, +11.3% vs 2020; organic net sales +4.5% vs 2020 and +8.4% vs 2019.
In connection with Mr. Stiles’s appointment as CEO, the Board also increased the size of the Board from 10 to 11 and appointed Mr. Stiles to serve as a member of the Board, effective January 1, 2027.
and that Spencer S. Stiles, who currently serves as President and Chief Operating Officer of the Company, has been appointed CEO of the Company, effective January 1, 2027.
Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the “Board”), effective January 1, 2027 (the “CEO Transition”)
On October 5, 2026, the Company entered into a letter agreement with Mr. Lobo (the “Transition Agreement”), pursuant to which (1) he will continue to serve as CEO of the Company through December 31, 2026, and (2) as of January 1, 2027, he will begin serving as Executive Chair of the Board.
Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026
William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026
On February 4, 2025, Allan Golston, a member of the Board of Directors (the “Board”) of Stryker Corporation (the “Company”), informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 8, 2025
Glenn S. Boehnlein has decided to retire from his role as Vice President, Chief Financial Officer of the Company effective April 1, 2025
Preston W. Wells, who currently serves as Vice President, Group Chief Financial Officer for Orthopaedics, has been promoted to Vice President, Chief Financial Officer of the Company effective April 1, 2025
On December 4, 2023, Dr. Srikant Datar, a member of the Board of Directors (the “Board”) of the Company, informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 9, 2024 (the “Annual Meeting”).
Timothy J. Scannell, President and Chief Operating Officer of the Company, has notified the Company of his intent to retire on March 31, 2023.
Effective October 1, 2021, Kevin A. Lobo, the Chair and Chief Executive Officer of the Company, will also become President of the Company.
Max materiality 0.85 · Median 0.72 · Most common event earnings